['Pancreatectomy can be complicated by pancreatic anastomotic leakage, causing major morbidity.', 'Our aim was to determine if vapreotide, a potent long-acting somatostatin analogue, would decrease pancreas-related complications. This prospective, multicenter, randomized, double-blind, placebo-controlled trial involved 275 patients without preexisting chronic pancreatitis undergoing elective proximal, central, or distal pancreatectomy. Complications were defined by objective criteria before beginning the study.', 'One hundred thirty-five patients received vapreotide; 140 patients received placebo. There were no statistically significant differences between vapreotide- and placebo-treated patients in either pancreas-related complications (30.4% versus 26.4%, respectively) or in other complications not directly related to the pancreas (40% versus 42%, respectively).'] Does the potent somatostatin analogue vapreotide decrease pancreas-specific complications after elective pancreatectomy : a prospective , multicenter , double-blinded , randomized , placebo-controlled trial?